SCHEMBL6650425

SCHEMBL6650425

CC[C@@H](C(N)=O)N1C[CH]CC1=O

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.54
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA3 P07451 1/20 0.54
CA4 P22748 1/20 0.54
CA6 P23280 1/20 0.54
CA5A P35218 1/20 0.54
CA7 P43166 1/20 0.54
CA9 Q16790 1/20 0.54
CA13 Q8N1Q1 1/20 0.54
CA14 Q9ULX7 1/20 0.54
CA5B Q9Y2D0 1/20 0.54
ALDH1A1 P00352 1/20 0.30
POLB P06746 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
DPP4 P27487 1/20 0.30
DPP8 Q6V1X1 1/20 0.30
DPP9 Q86TI2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16058913 1.00 LMNA (0.54) LMNACA12CA1CA2CA3
SCHEMBL2333742 0.76 LMNA (0.50) LMNACA12CA1CA2CA3
SCHEMBL3046245 0.76 LMNA (0.50) LMNACA12CA1CA2CA3
SCHEMBL10279873 0.71 LMNA (0.49) LMNACA12CA1CA2CA3
Levitiracetam SCHEMBL61493 0.70 LMNA (1.00) LMNACA12CA1CA2CA3
Etiracetam SCHEMBL373194 0.70 LMNA (1.00) LMNACA12CA1CA2CA3
Levetiracetam SCHEMBL118843 0.70 LMNA (1.00) LMNACA12CA1CA2CA3
Levetiracetam SCHEMBL5072485 0.70 LMNA (1.00) LMNACA12CA1CA2CA3
SCHEMBL660679 0.69 LMNA (0.90) LMNACA12CA1CA2CA3
Etiracetam SCHEMBL22031970 0.69 LMNA (0.97) LMNACA12CA1CA2CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2968220-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION Agenebio, Inc. (US) 2016-01-20 EP disclosed
EP-2919788-A1 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA The Johns Hopkins University (US) 2015-09-23 EP disclosed
WO-2014144801-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION AGENEBIO INC. (US) 2014-09-18 WO disclosed
WO-2014078568-A1 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA THE JOHNS HOPKINS UNIVERSITY (US) 2014-05-22 WO disclosed
EP-1447399-A1 \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ UCB, S.A. (BE) 2004-08-18 EP disclosed